Sunrise Energy – Speculative Buy

Posted on | by Leon Hinde

Sunrise Energy Metals is progressing its world-class Sunrise Battery Materials Complex in New South Wales.

The Sunrise Project is one of the largest and most cobalt-rich nickel laterite deposits in the world and is development-ready, with all key permits and approvals in place.  Sunrise is also one of the largest and highest grade scandium deposits globally.

The company requires a funding solution, (or JV partnership), to continue the development of the Sunrise project and we expect to hear news on this front within 6 – 9 months.

SRL is a high risk, high reward speculative opportunity, however, we feel the risks are skewed to the upside and traders may wish to run a stop loss on a break below $1.60

Cure ETF – Buy

Posted on | by Leon Hinde

CURE:AXW is under Algo Engine buy conditions and the current pullback provides another buying opportunity.

ETFS S&P Biotech ETF (ASX Code: CURE) offers investors exposure to U.S. biotechnology companies. These companies are engaged in research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering.

.

Pexa – Accumulate

Posted on | by Leon Hinde

Pexa Group has helped transform conveyancing from a clunky paper-based process into a digital one. PXA was recently listed on the ASX with a market cap of $3bn.

FY21 underlying earnings are expected to double to $108 million, before rising a further 20% in FY22.

CBA & Link are major shareholders.

Call Options Jump 40%

Posted on | by Leon Hinde

Following a better 1H21 earnings result for CIMIC, the Dec $20 call options increased 40%.

We continue to see CIMIC as a recovery opportunity, supported by an improving balance sheet and increasing work in hand.

Northern Star – Strong Production

Posted on | by Leon Hinde

Northern Star Resources is under Algo Engine buy conditions and is our preferred gold exposure.

NST continues to deliver strong results in the June quarter. Group production finished with 450koz at $1460oz, (up 23%), whilst seeing costs come down almost 10%.

We continue to see the twin factors of a strong gold price and cost-saving, (post-merger with SAR), helping to support the share price.

Buy NST